Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan.
College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Front Immunol. 2022 Jul 5;13:905727. doi: 10.3389/fimmu.2022.905727. eCollection 2022.
Treatment responsiveness to corticosteroids is excellent for cryptogenic organizing pneumonia (COP) and sarcoidosis, but suboptimal for idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP). We hypothesise that the differential expression of IL-17 contributes to variable corticosteroid sensitivity in different interstitial lung diseases.
To determine the associations among expression of IL-17, glucocorticoid receptor-β and responsiveness to corticosteroid treatment in interstitial lung diseases.
Immunohistochemical (IHC) staining was performed on formalin-fixed paraffin-embedded (FFPE) lung tissues obtained by bronchoscopic, CT-guided or surgical biopsies, and quantified by both cell counting (% positive cells) by individuals and by software IHC Profiler plugin of ImageJ (opacity density score). We studied the effect of IL-17 on corticosteroid sensitivity in human fibroblast MRC5 cell line.
Compared with specimens from patients with COP (n =13) and sarcoidosis (n =13), those from IPF patients (n = 21) had greater GR-β and IL-17 expression and neutrophil infiltration. Radiographic progression after oral corticosteroid treatment was positively correlated with the expression in IL-17 and GR-β/GR-α ratio in all patients (COP, sarcoidosis and IPF) and also within the IPF subgroup only. IL-17 expression level was positively associated with GR-β and GR-β/GR-α ratio. In MRC5 cells, exogenous IL-17 increased the production of collagen I and up-regulated GR-β expression and dexamethasone's suppressive effect on collagen I production was impaired by IL-17, and silencing IL-17 receptor A gene attenuated the effect of IL-17.
Up-regulation of GR-β/GR-α ratio by IL-17 could be associated with the relative corticosteroid-insensitivity of IPF.
对于隐源性机化性肺炎(COP)和结节病,皮质类固醇治疗反应性极好,但特发性肺纤维化(IPF)/寻常间质性肺炎(UIP)则不然。我们假设白细胞介素 17(IL-17)的差异表达导致不同间质性肺病中皮质类固醇敏感性的不同。
确定 IL-17 的表达与间质性肺疾病中糖皮质激素治疗反应性之间的关系。
通过支气管镜、CT 引导或手术活检获得福尔马林固定石蜡包埋(FFPE)肺组织,进行免疫组织化学(IHC)染色,并由个体进行细胞计数(%阳性细胞)和 ImageJ 的 IHC Profiler 插件(不透明度密度评分)进行定量。我们研究了 IL-17 对人成纤维细胞 MRC5 细胞系中皮质类固醇敏感性的影响。
与 COP(n=13)和结节病(n=13)患者的标本相比,IPF 患者(n=21)的 GR-β 和 IL-17 表达以及中性粒细胞浸润更高。所有患者(COP、结节病和 IPF)以及仅在 IPF 亚组中,口服皮质类固醇治疗后的影像学进展与 IL-17 和 GR-β/GR-α 比值的表达呈正相关。IL-17 表达水平与 GR-β 和 GR-β/GR-α 比值呈正相关。在 MRC5 细胞中,外源性 IL-17 增加了胶原 I 的产生,并上调了 GR-β 的表达,而 IL-17 削弱了地塞米松对胶原 I 产生的抑制作用,沉默 IL-17 受体 A 基因减弱了 IL-17 的作用。
IL-17 上调 GR-β/GR-α 比值可能与 IPF 相对皮质类固醇不敏感有关。